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Abstract
Background: Gut is the major source of endogenous bacteria causing infections in advanced cirrhosis. Intestinal barrier
dysfunction has been described in cirrhosis and account for an increased bacterial translocation rate.
Hypothesis and Aims: We hypothesize that microbiota composition may be affected and change along with the induction
of experimental cirrhosis, affecting the inflammatory response.
Animals and Methods: Progressive liver damage was induced in Balb/c mice by weight-controlled oral administration of
carbon tetrachloride. Laparotomies were performed at weeks 6, 10, 13 and 16 in a subgroup of treated mice (n=6/week)
and control animals (n=4/week). Liver tissue specimens, mesenteric lymph nodes, intestinal content and blood were
collected at laparotomies. Fibrosis grade, pro-fibrogenic genes expression, gut bacterial composition, bacterial
translocation, host’s specific butyrate-receptor GPR-43 and serum cytokine levels were measured.
Results: Expression of pro-fibrogenic markers was significantly increased compared with control animals and correlated
with the accumulated dose of carbon tetrachloride. Bacterial translocation episodes were less frequent in control mice than
in treated animals. Gram-positive anaerobic Clostridia spp count was decreased in treated mice compared with control
animals and with other gut common bacterial species, altering the aerobic/anaerobic ratio. This fact was associated with a
decreased gene expression of GPR43 in neutrophils of treated mice and inversely correlated with TNF-alpha and IL-6 up-
regulation in serum of treated mice along the study protocol. This pro-inflammatory scenario favoured blood bacterial
translocation in treated animals, showing the highest bacterial translocation rate and aerobic/anaerobic ratio at the same
weeks.
Conclusions: Gut microbiota alterations are associated with the development of an inflammatory environment, fibrosis
progression and bacterial translocation in carbon tetrachloride-treated mice.
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Introduction
Gut microbiota is a large and diverse population of living
microorganisms highly susceptible to environmental and patho-
physiological alterations [1]. It exerts nutritional, protective and
trophic effects on the intestinal epithelium and immune system,
maintaining symbiotic mutualistic interactions with the host [2,3].
The gut microbiota is also a dynamic ecosystem that modifies its
composition and physiological functions in response to severe
habitat insults. Original studies on mice showed that gastrointes-
tinal microbiota is mainly composed by Enterobacteriaceae, Lactoba-
cillus, Bacteroides and Clostridium [4;5]. Some Clostridium clusters are
involved in the production of short chain fatty acids like butyrate
used as fuel for host’s colonocytes [6]. In addition, butyrate has
anti-inflammatory effects that result from inhibition of transcrip-
tion factor NF-kB leading to a decreased secretion of pro-
inflammatory cytokines [7–9]. Other bacterial groups such as
Bifidobacterium also seem to be implicated in host’s protection by
preventing increased permeability and promoting a healthier
microvillus environment [10,11].
Experimental chronic liver damage is commonly associated with
a several-fold increase of bacterial translocation (BT) [12,13]. BT
is a common and recurrent event occurring in cirrhosis and
constitutes the current pathogenic theory for the onset of bacterial
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e23037infections in this setting [14–16]. Intestinal bacterial overgrowth,
increased permeability of the intestinal mucosal barrier, and
deficiencies in local host immune defences are the major
mechanisms postulated to favour BT in cirrhosis [17,18]. Any of
these abnormalities deranges clearance of endogenous bacteria
from portal and systemic circulation, turning the gut into the
major source of bacteria in life-threatening bacterial infections
such as spontaneous bacterial peritonitis (SBP) [19].
We therefore hypothesize that microbiota composition may be
affected and change along with the progressive liver damage
induced in mice by oral administration of carbon tetrachloride
(CCl4). From this point, the aim of this study has been to provide
integrative data on inflammatory consequences associated with
alterations in the gut microbiota composition and bacterial
translocation, defined by presence of bacterial DNA in MLNs
and blood [13], in mice with advanced CCl4-induced liver
damage.
Results
Characteristics of animals and progressive liver injury
A total of 75 animals were included in the study. Fifty of them
were weekly treated with CCl4 (see methods) and 25 mice
constituted the control group. Twenty animals (40%) died during
liver damage induction (treated group). None of the control
animals died during the study protocol. Characteristics of control
and treated mice at weeks of laparotomy, histopathological
progressive liver damage induced and the evolution of profibro-
genic markers during the study protocol can be followed in Table 1
and Figure 1, respectively. Regenerative nodules in treated
animals were considered as evidences of cirrhosis. Expression of
all profibrogenic markers was significantly increased from week 6
when compared with levels in non-treated mice. The highest
relative expression of all profibrogenic markers and the most
severe liver fibrosis happened at week 13. Accumulated dose of
CCl4 correlated with relative gene expression of all profibrogenic
markers (vs TGF-B, r=0.883; vs MMP-2, r=0.887; vs ProCol-1,
r=0.893; vs TIMP-1, r=0.883; p,0.001 in all cases).
Alterations in gut microbiota content during induction of
cirrhosis are associated with blood inflammatory events
The effect of continuous administration of CCl4 to mice on gut
microbiota composition was evaluated and compared with control
animals at several stages during the study protocol (Table 2). As
can be observed, no statistical differences were detected for
Enterobacteriaceae, Lactobacillus group and Bacteroides fragilis group
between control and treated animals at different weeks. In the case
of the Bifidobacterium genus, despite initial differences in concen-
tration between control and treated mice, its numbers became
very similar from week 10 on. However, numbers of Clostridium
leptum group and Clostridium coccoides group were significantly
reduced in treated animals compared with control mice from week
6 to the end of the study time-frame. Figure 2 shows the ratio of
Enterobacteriaceae to Clostridium groups in control and treated mice,
as an index of the proportion of aerobic bacteria in relation to
anaerobic bacteria in the intestinal contents. Whereas this ratio
was constant along the study protocol for control animals, it
significantly increased in treated mice along the study weeks.
To determine a possible relationship between inflammation and
decreased Clostridium numbers in the intestine of treated mice,
temporal mRNA expression of butyrate specific G protein-coupled
receptor (GPR)-43 was analyzed in PMN cells of treated and control
mice.Figure3showsa statisticallysignificant GPR43decreaseincells
from CCl4-treated mice compared with control mice from week 10,
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PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e23037atwhichthelowestlevelsofGPR43areobserved.Ascanbefollowed,
variations in GPR43relative mRNA expressionare similar as those of
Clostridium group numbers along the weeks. In fact, a positive
correlation was obtained between GPR43 relative gene expression
levels and the Clostridium group numbers when the total series of mice
included in the study were considered.
Pro-inflammatory cytokines TNF-a and IL-6 were also
evaluated in blood of treated and control mice. Treated mice
showed significantly higher levels of TNF-a and IL-6 at every
week of study compared with control mice, reporting the highest
levels of both cytokines at week 10 (Figure 4A). Serum levels of
these cytokines inversely correlated with the concentration of C.
coccoides group and C. leptum group, as can be observed in Figure 4,
and with GPR43 relative gene expression (r=20.72, p=0.01 in
the case of TNF-a; and r=-0.78, p=0.01 in the case of IL-6).
Rate of bacterial translocation episodes is associated with
gut dysbiosis and liver damage progression
BT, defined by presence of bacterial DNA in MLNs and blood
[13],wasevaluatedatlaparotomiesalongthestudyprotocol(Table3).
Figure 1. Fibrosis grade at laparotomy weeks along the study protocol in CCl4-treated mice. (A) Example of histological changes in CCl4-
treated mice along the 16 weeks of study. Hepatic sections stained with Masson Trichrome (original magnification610), showing light to strong blue
staining, as a reflection of the collagen deposition at different stages of the liver disease: no histopathological changes (week 0); focal mild portal
fibrosis with short fibrous septa (week 6); moderate collagen fibber deposition in portal areas with occasional portal bridging (week 10); marked
fibrosis in the majority of portal spaces with frequent portal-portal and portal-central bridging and architectural distortion (regenerative nodules)
(weeks 13 and 16). (B) Fibrosis grade according to Ishak Scale in treated animals (n=6/week) at different study weeks are represented as mean 6
standard deviation. (C) Relative gene expression levels of different profibrogenic genes at different study weeks. MMP-2: Matrix metalloproteinase 2;
TGF-b. Tumour growth factor beta; ProCol-1: Procollagen alpha-1(1); TIMP-1: Tissue inhibitor of metalloproteinase 1. Mean values of CCl4-treated mice
(n=6/week) are represented.
doi:10.1371/journal.pone.0023037.g001
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PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e23037Overall, bacterial DNA translocation was more frequently present in
treated animals (14/24, 58.3%) compared with control mice (3/22,
13.6%, p,0.05). All animals with bacterial DNA in MLNs except for
one in the treated group showed simultaneous presence of the
corresponding bacterial DNA in blood. Sequencing analysis
identified Escherichia coli in 10 samples (8 from treated and 2 from
Figure 2. Temporal evolution of Clostridium groups and Enterobacteriaceae counts and their ratio in control and CCl4-treated mice. (A,
B, C) Bacterial counts from samples of cecum content were measured by quantitative real-time PCR and represented as Log cell/g intestinal content.
Values shown as mean 6 standard deviation are represented for control (n=4/week) and treated mice (n=6/week) along the 16 weeks of study. (D)
Differences in the Enterobacteriaceae/Clostridia ratio are represented as mean 6 standard deviation for control (n=4/week) and treated mice (n=6/
week) along the 16 weeks of study.
doi:10.1371/journal.pone.0023037.g002
Table 2. Gut microbiota changes during the study protocol in control and CCl4-treated mice.
week 0 week 6 week 10 week 13 week 16
Bacterial
cluster
(counts) control (n=6) control (n=4) CCl4 (n=6) control (n=4) CCl4 (n=6) control (n=4) CCl4 (n=6) control (n=4) CCl4 (n=6)
Enterobacteriae 10,3 6 1,34 15,66 6 1,74 17,29 6 3,74 12,45 6 1,42 13,38 6 4,32 19,78 6 3,19 17,43 6 3,63 9,89 6 2,49 13,62 6 1,52
Lactobacillus 15,7 6 0,83 16,71 6 0,44 17,56 6 1,34 16,55 6 1,24 14,49 6 1,89 16,22 6 1,47 17,88 6 1,04 16,24 6 0,95 14,23 6 1,12
Bacteroides 12,7 6 0,96 15,76 6 2,49 18,33 6 1,84 17,10 6 0,60 16,47 6 1,09 19,10 6 1,52 18,50 6 1,39 14,57 6 1,28 15,94 6 0,98
Bifidus 10,1 6 2,13 7,91 6 0,88 12,82 6 1,04 * 17,00 6 2,42 13,13 6 1,73 * 13,84 6 0,41 13,45 6 1,36 12,66 6 1,10 14,70 6 2,33
C. leptum 12,7 6 0,82 16,64 6 2,43 17,25 6 2,24 18,48 6 0,71 12,65 6 1,43 * 19,24 6 1,04 14,99 6 2,06 * 16,98 6 1,41 12,20 6 2,64 *
C. coccoide 15,2 6 1,16 17,19 6 1,51 17,94 6 1,87 19,52 6 0,25 12,61 6 1,06 * 19,12 6 0,78 15,26 6 1,05 * 19,52 6 0,99 15,52 6 0,79 *
Bacterial counts: Log cells/g intestinal content:
** p,0.05 compared with weekly control mice.
doi:10.1371/journal.pone.0023037.t002
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1 from control mice), and Staphylococcus aureus in 2 samples, Shigella
flexneri in 1 sample and Campylobacter jejuni in 1 sample from treated
mice. This last species corresponded to the single discrepancy
between bacterial DNA identified inMLNs and notin blood. Theuse
of species-specific primers in MLN samples corroborated first, the
presence of the sequenced bacterial DNA and, second, the absence of
other simultaneous species.
BT rate in control mice was not increased along the study weeks.
However, in the group of treated animals, percentage of BT episodes
was incremented at weeks 13 and 16 along with fibrosis grade, from
17% of BT present in non-fibrotic mice up to more than 80% of mice
with the most severe fibrotic grades, and with gut dysbiosis, reaching
the highest rate at the same week aerobic/anaerobic ratio was higher.
Serum levels of both cytokines were significantly higher in animals with
BT compared with non-BT mice, independently of the study week
(TNF-a, 29.068.1 pg/mL vs 21.568.1 pg/mL, p,0.05; IL-6,
20.863.8 pg/mL vs 15.863.4 pg/mL, p,0.05).
Discussion
The present study shows that a decrease in Clostridium group
numbers in gut microbiota content is associated with an increased
inflammatory response and liver injury progress in CCl4-treated
mice. This dysbiosis is, in turn, timely associated with and
increased rate of bacterial DNA translocation episodes in treated
mice, suggesting a key role for gut microbiota changes in the
development of BT during induction of experimental cirrhosis.
Cirrhosis represents the end-stage of any chronic liver disease,
characterized by the most advanced stage of fibrosis, distortion of
the liver parenchyma associated with septae and nodule formation,
altered blood flow and the potential development of liver failure at
long term. Bacterial infections are common complications in
patients with decompensated cirrhosis and are thought to happen
by deficiencies in the host immune defences, impairment in
permeability of the intestinal mucosal barrier and/or intestinal
bacterial overgrowth [17,18]. All these factors are postulated to
favour BT in advanced cirrhosis, which has already been
demonstrated in experimental cirrhosis [13,20]. As all suggested
BT mechanisms are related to alterations in the intestinal
microbiota, which constitutes the major source of endogenous
bacteria, in the present work we have evaluated the quantitative
changes in the main clusters of gut microbiota in mice and the
associated inflammatory status along the induction of experimen-
tal cirrhosis in the final outcome of an increased BT risk.
Figure 3. Specific G protein-coupled receptor (GPR)-43 gene expression along the study protocol. (A) Temporal mRNA expression of
GPR-43 in PMN cells of treated and control mice. Values were measured by quantitative real-time PCR and are shown as mean 6 standard deviation
for control (n=4/week) and treated mice (n=6/week) along the 16 weeks of study. (B) Relative mRNA expression of GPR-43 PMN levels, and C. leptum
and C. coccoides counts from samples of intestinal cecum content in treated animals (n=6/week) are shown at different laparotomy weeks. (C, D)
Correlation between GPR-43 PMN gene expression levels and C. leptum (C) or C. coccoide (D) counts in all control (n=22) and treated mice (n=24)
included in the study.
doi:10.1371/journal.pone.0023037.g003
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were followed for 16 weeks and compared with control mice, as
described in Methods section. During this period, expression of
pro-fibrogenic markers was significantly increased compared with
control animals, and correlated with the accumulated dose of
CCl4. As expected, BT episodes were less frequent in control mice
than in treated animals and, among them, BT incidence increased
as fibrosis grade did. But one of the most relevant findings in this
investigation was that, in this time-frame, the numbers of Gram-
positive anaerobic Clostridium groups decreased in treated mice
compared with control animals and with other gut common
bacterial groups, increasing the aerobic/anaerobic bacterial ratio
and, probably, impairing its balance. BT episodes in treated
animals increased similarly to this ratio and were more frequent in
animals with higher aerobic/anaerobic bacterial ratios. Of
interest, total numbers of Enterobacteriaceae were increased in mice
showing translocation of E. coli to MLNs, although differences did
not reach statistical significance. Prevalence of each particular
translocating species in MLNs could not be quantified in the
corresponding gut sample, since number of gene copies was found
below our detection limit (10
3 copies) in all cases (data not shown).
Symbiotic mutualistic interactions between gut microbiota and
the host are delineated at several physiological levels. Gut
microbiota, for example, fulfils metabolic roles such as generation
of short-chain fatty acids (SCFAs) that constitute an energy source,
particularly for the host colonocytes [21]. Of the main SCFAs
generated in the gut, butyrate also has the ability of suppressing
inflammatory cytokine secretion by blocking NF-kB [22].
Although butyrate is mainly used at gut epithelium, polymorph-
nuclear (PMN) cells express a specific receptor for butyrate
(GPR43) and other SCFAs like propionate and can be involved in
Figure 4. Pro-inflammatory cytokine profile along the study protocol. (A) TNF-a and IL-6 serum levels in control (n=4/week) and treated
mice (n=6/week). Values, measured by cytometric bead arrays, obtained from each single mouse at different study weeks are represented in the
Figure. *p,0.05 compared with the weekly control group. (B) Correlation between serum TNF-a and IL-6 with C. coccoides counts from samples of
intestinal cecum content in all control (n=22) and treated mice (n=24) included in the study. (C) Correlation between serum TNF-a and IL-6 with C.
leptum counts from samples of intestinal cecum content in all control (n=22) and treated mice (n=24) included in the study.
doi:10.1371/journal.pone.0023037.g004
Table 3. Bacterial DNA translocation at laparotomies in
control and treated mice.
Control mice (n=22) Treated mice (n=24)
Week MLNs Blood MLNs Blood
0 0/6 (0%) 0/6 (0%) 22
6 1/4 (25%) 1/4 (25%) 1/6 (17%) 1/6 (17%)
10 0/4 (0%) 0/4 (0%) 3/6 (50%) * 2/6 (33%) *
13 1/4 (25%) 1/4 (25%) 5/6 (83%) * 5/6 (83%) *
16 1/4 (25%) 1/4 (25%) 5/6 (83%) * 5/6 (83%) *
*p,0,05 compared with the weekly control group; MLNs: mesenteric lymph nodes.
doi:10.1371/journal.pone.0023037.t003
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measured, the dysbiosis observed in our study was also associated
with a decreased gene expression of its specific receptor GPR43 in
neutrophils of treated mice. Since butyrate is mainly produced by
species of the Clostridium clusters analysed such as the cluster XIV
(C. coccoides group) and cluster IV (C. leptum group) that included
Faecalibacterium prausnitzii, one of the main intestinal butyrate
producer bacterium [24], and is implicated in the host’s anti-
inflammatory response, an enhanced pro-inflammatory response
might be facilitated as a consequence of Clostridium groups
decreased counts. In agreement with that, pro-inflammatory
cytokines TNF-a and IL-6 were significantly increased in serum
of treated mice and nicely correlated with the decrease of numbers
of these Clostridium clusters and the GPR43 expression (Figures 3
and 4). GPR43 also participates in recruitment of other PMNs to
prevent BT [23]. Accordingly, when Clostridium group numbers
were reduced, GPR43 expression was down-regulated and pro-
inflammatory cytokines were secreted, BT episodes were increased
in treated animals, correlating with the aerobic/anaerobic
bacterial ratio increase. In fact, BT has been associated with
aerobic bacterial overgrowth [17]. All these findings suggest a role
for microbiota changes in the development of BT episodes in
treated mice.
It has been largely discussed whether BT induces inflammation
or is facilitated by a pro-inflammatory environment [12]. While
both probably feedback each other, in this model of liver damage,
inflammation seems to be an early event in response to injure,
likely as a consequence of a decrease in Gram-positive anaerobic
Clostridium group numbers. This fact might help in providing the
favourable conditions for fibrosis progression and BT. In fact,
TNF-a, a key factor associated with fibrosis progression in many
different types of chronic liver diseases [25,26], is also associated
with development of BT in rats subjected to induced liver damage
with CCl4, hemorrhagic shock or with injection of endotoxin
[12,27-29]. Figure 5 resumes a list of events along the weeks of the
study protocol in treated animals.
In summary, besides the important role that gut microbiota
plays in the pathogenesis of complications in established cirrhosis
such as bacterial infections, mainly caused by translocation of
enteric Gram-negative microorganisms [19], we here suggest a
role for alterations in intestinal microbiota composition in the
development of an inflammatory outlook that may favour BT
during early stages and progression of fibrosis. Although we cannot
exclude the possibility that the altered gut flora composition was a
result of CCl4 administration, these results enhance the relevance
of promoting gut homeostasis to prevent adverse events such as BT
in the setting of chronic liver damage.
Methods
Ethics statement
Animals received care according to the criteria outlined in the
Guide for the Care and Use of Laboratory Animals. The study was
approved by the Animal Research Committee of Universidad Miguel
Hernandez (Alicante,Spain) with approval numberHA-RFG-002-09.
Animals and induction of liver damage
Female Balb/c mice (Harlan, Barcelona, Spain) were included
in a 16-week study protocol. Mice were caged at a constant room
temperature of 21uC and exposed to a 12:12 light/dark cycle.
Mice weighting 18–20 g were fed standard rodent chow and were
treated with 0.25 mmol/L phenobarbital in tap water along the
study protocol. After a 4-week housing in those conditions, animals
received two weekly doses of CCl4 (Sigma Aldrich, Madrid, Spain)
that were intragastrically administered using a sterile pyrogen free
syringe with an attached stainless steel animal feeding tube without
anaesthesia. The first dose of CCl4 was (100 uL/kg) in mineral oil,
and subsequent doses were adjusted based on changes in weight
48 hours after the last dose. A second group of animals were used
as controls. This group was fed standard rodent chow and treated
with 0.25 mmol/L phenobarbital in tap water along the study
protocol, and received two weekly doses of mineral oil (0.2 mL).
Laparotomy and sample collection
Laparotomies were performed at 6, 10, 13 and 16 weeks in a
subgroup of treated mice (n=6/week) and at 0, 6, 10, 13 and 16
weeks in a subgroup of control animals (n=4/week). Laparoto-
mies were performed under anaesthesia with isofluorane. Abdom-
inal fur was removed with a depilatory, and the skin was sterilized
with iodine. A short incision in the abdominal wall was performed
and all detectable mesenteric lymphatic nodes (MLNs), especially
from the ileo-cecal area, were aseptically dissected and removed.
Figure 5. Temporal pattern of key events related with development of bacterial DNA translocation in CCl4-treated mice. The lowest
levels of cytokine production, PMN butyrate specific-receptor GPR43 and Clostridium clusters counts from samples of intestinal cecum content along
with the highest degrees of liver fibrosis, gut dysbiosis and bacterial translocation observed in treated animals are chronologically represented during
the 16 weeks of study protocol.
doi:10.1371/journal.pone.0023037.g005
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injection and total blood collection. Liver, spleen and intestinal
content from ileum (10cm) and cecum were collected. Histopath-
ological, microbiological and molecular studies were performed in
all collected samples.
Histological analysis
Forty-six liver biopsy specimens between 10 to 15 mm in size
were fixed in buffered formalin and embedded in paraffin.
Histologic changes were first evaluated by routine hematoxilin
and eosin (H&E) in four-micrometer thick sections. We estimated
Table 4. List of primer pairs used in the study.
Gene Sequence (59–39) References
b-2 microglobulin GTGACCCTGGTCTTTCTGGT
ATCCCAGTAGACGGTCTTGG
Procollagen a1 type I TCCGGCTCCTGCTCCTCTTA
GTATGCAGCTGACTTCAGGGATGT
Matrix metalloproteinase (MMP)-2 CCGAGGACTATGACCGGGATAA
CTTGTTGCCCAGGAAAGTGAAG
Tumour growth factor (TGF)-b CCTGAGTGGCTGTCTTTTGA
CAACCCAGGTCCTTCCTAAA
Tissue inhibitor of metalloproteinase (TIMP)-1 TCCTCTTGTTGCTATCACTGATAGCTT
CGCTGGTATAAGGTGGTCTCGTT
16S rRNA AGAGTTTGATCATGGCTCAG [13]
ACCGCGACTGCTGCTGGCAC
G protein-coupled receptor (GPR) 43 CCAAGGAGTTCTGGCAGGTGGCT [32]
AGCGCGCACACGATCTTTGGT
Target bacterial group/species
Total bacteria TGGCTCAGGACGAACGCTGGCGGC [33]
CCTACTGCTGCCTCCCGTAGGAGT
Bacteroides fragilis group ATAGCCTTTCGAAAGRAAGAT [33,34]
CCAGTATCAACTGCAATTTTA
Clostridium coccoides group AAATGACGGTACCTGACTAA [33,34]
CTTTGAGTTTCATTCTTGCGAA
Clostridium leptum group GCACAAGCAGTGGAGT [33,34]
CTTCCTCCGTTTTGTCAA
Enterobacteriaceae CATTGACGTTACCCGCAGAAGAAGC [35]
CTCTACGAGACTCAAGCTTGC
Lactobacillus group GGAAACAG(A/G)TGCTAATACCG [36,37]
CACCGCTACACATGGAG
Bifidobacterium CTCCTGGAAACGGGTGG [33,34]
GGTGTTCTTCCCGATATCTACA
E. coli GTTAATACCTTTGCTCATTGA [35]
ACCAGGGTATCTAATCCTGTT
K. pneumoniae TGAAATATGACTCCACTCACGG
CTTCAGAAGCGGCTTTGATGGCTT
Enterococcus spp. CCCTTATTGTTAGTTGCCATCATT [35]
ACTCGTTGTACTTCCCATTGT
S. pneumoniae AAGGAGGGGTGTGTAC [38]
GTACAACGAGTCGCAAGC
S. aureus GGCCGTGTTGAACGTGGTCAAATCA [39]
TACCATTTCAGTACCTTCTGGTAA
Shigella group GTTCCTTGACCGCCTTTCCGATAC [40]
CATTTCCTTCACGGCAGTGGA
C. jejuni GAAGAGGGTTTGGGTGGTG [41]
AGCTAGCTTCGCATAATAACTTG
doi:10.1371/journal.pone.0023037.t004
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connective tissue stain Masson trichrome. The amount of fibrosis
was blindly assessed semiquantitatively based on the Ishak score
[30] by a single senior pathologist (GP), with a conventional light
microscope (Olympus BX50, Barcelona, Spain).
Gene expression analysis
Total cellular RNA was isolated from 20–30 mg of liver
disrupted by sonication (Hielscher UP100H Ultrasonic Processor,
Teltow, Germany) to determine expression of profibrogenic
tumour growth factor beta (TGF-b)-1, Procollagen a-1(1)
(ProCol-1), tissue inhibitor of metalloproteinase (TIMP)-1 and
matrix metalloproteinase (MMP)-2 genes and from 5610
6 blood
polymorphonuclear (PMN) cells by handling QIAmp RNA Blood
Minikit (QIAgen, Hilden, Germany) for quantitation of G Protein-
coupled Receptor (GPR)-43, a specific butyrate-receptor gene.
Quantitec SYBR Green (QIAgen) was used to perform gene
expression in an IQ5 Real-Time PCR (BioRad, Hercules, CA).
Table 4 resumes primer pair sequences used in the study. Primer-
BLAST tool from NCBI (National Center for Biotechnology
Information, U.S. National Library of Medicine) was used to
design specific primers for studied profibrogenic genes.
Identification of bacterial DNA
Bacterial DNA presence was detected and identified in blood
and MLNs. Extraction of total DNA was carried out by using the
QIAamp DNA blood Mini kit (QIAgen), according to the
manufacturer’s instructions. A broad-range polymerase chain
reaction (PCR) followed by nucleotide sequencing of 16SrRNA
gene was performed according to the methodology described
elsewhere [31]. Species-specific primers (Table 4) were also used to
test simultaneous presence of several species by conventional PCR.
Microbial composition analysis by quantitative PCR
(qPCR)
Samples of intestinal content from cecum were frozen
immediately after collection at -20uC and stored until analyzed.
Samples were weighed and diluted 1:5 (wt/vol) in phosphate-
buffered saline (pH 7.2) homogenized and one aliquot of this
dilution was used for DNA extraction. Extraction of total DNA
from fecal samples was carried out by using the QIAamp DNA
stool Mini kit (QIAgen) according to the manufacturer’s
instructions. The DNA obtained in the samples was measured
with a ND-1000 spectrophotometer based absorbance at 260 nm
(NanoDrop, Wilmington, DE).
Specific primers (Table 4) targeting different bacterial genera
were used to characterize the main gut bacterial groups by
quantitative real-time PCR. PCR amplification and detection
were performed with LightCyclerH480 Real-Time PCR System
(Roche, Barcelona, Spain). Each reaction mixture (15 mL)
consisted of LightCyclerH 480 SYBR Green I Master (Roche),
0.75 mL of each of the specific primers at a concentration of
10 mM, and 60 ng of template DNA. The fluorescent products
were detected at the last step of each cycle. A melting curve
analysis was made after amplification to distinguish the targeted
PCR product from the non-targeted PCR product. Bacterial
concentration from each sample was calculated by comparing the
Ct values obtained from the standard curves. Standard curves
were created using serial 10-fold dilution of pure cultures of DNA,
corresponding to 10
2 to 10
9 cells from the culture collection, as
determined by microscopy counts using DAPI.
Serum Cytokine Levels
Enzyme-linked immunosorbent assays (ELISAs) were carried
out for IL-6 and TNF-a (Human Quantikine kits, R&D Systems,
Minneapolis, MN) according to the manufacturers’ instructions.
All samples were tested in triplicate and read in a Sunrise
Microplate Reader (Tecan, Ma ¨nnedorf, Switzerland). Lower limit
of detection for each assay was 5 pg/mL. Standard curves were
generated for every plate and the average zero standard optical
densities were subtracted from the rest of the standards, controls,
and samples to obtain a corrected concentration.
Statistical analysis
Continuous variables are reported as mean 6 standard
deviation and categorical variables as frequency or percentages.
Statistical differences of basal characteristics between groups were
analyzed using the Chi test for categorical data and the Mann-
Whitney U test for quantitative data. Bivariate correlations
between continuous variables were calculated using the Spearman
test. All reported P values are 2-sided, and P values lower than
0.05 were considered to indicate significance. All calculations were
performed using the SPSS 16.0 software (SPSS, Inc, Chicago, IL).
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